AN TRAN: Open Payments
NPI 1790231801 · LONGMONT, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$501 in 20 payments from 10 companies in 2025. Trend: 2023 $603 · 2024 $798 · 2025 $501
Food & beverage: $501
| Company | Payments | Amount |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 5 | $162 |
| PFIZER INC. | 5 | $124 |
| E.R. Squibb & Sons, L.L.C. | 2 | $40 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $37 |
| Novo Nordisk Inc | 1 | $33 |
| Merck Sharp & Dohme LLC | 1 | $26 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $25 |
| Amgen Inc. | 1 | $24 |
| SCPHARMACEUTICALS INC. | 1 | $15 |
| HEARTFLOW, INC. | 1 | $15 |
Products named: AMVUTTRA, VYNDAQEL, CAMZYOS, JARDIANCE, Wegovy, VERQUVO, Kerendia, REPATHA.
Industry payments across CO — which companies pay providers there.
